PORTFOLIO NEWS FLX Bio Named By FierceBiotech as One of its “Fierce 15” Biotech Companies of 2018 October 3, 2018 Read More » NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer October 1, 2018 Read More » Gritstone Oncology Announces Pricing of Initial Public Offering September 27, 2018 Read More » Constellation Pharmaceuticals Announces Pricing of Initial Public Offering July 18, 2018 Read More » Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins May 18, 2018 Read More » Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs May 9, 2018 Read More » Nurix Appoints Nancy Pryer, Ph.D., Chief Development Officer May 8, 2018 Read More » ORIC Has Appointed Jacob Chacko, MD as Chief Executive Officer May 7, 2018 Read More » REVOLUTION Medicines Raises $56 Million Series B Financing at $1.50 per share April 24 2018 Read More » eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting April 16, 2018 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
FLX Bio Named By FierceBiotech as One of its “Fierce 15” Biotech Companies of 2018 October 3, 2018 Read More »
NGM Bio Appoints David J. Woodhouse, Ph.D. as Chief Executive Officer and Aetna Wun Trombley, Ph.D. as President and Chief Operating Officer October 1, 2018 Read More »
Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins May 18, 2018 Read More »
Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs May 9, 2018 Read More »
REVOLUTION Medicines Raises $56 Million Series B Financing at $1.50 per share April 24 2018 Read More »
eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting April 16, 2018 Read More »
